Sinopharm | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
March 26, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, MARCH 26, 2023

Sinopharm

FILE PHOTO: A vial labelled "Sinopharm COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

Some Omicron sub-variants escaping antibodies from Sinopharm shot

Sinopharm protein-based booster stronger against Omicron than earlier shot -study
Coronavirus chronicle

Sinopharm protein-based booster stronger against Omicron than earlier shot -study

Test tubes are seen in front of a displayed Sinopharm logo in this illustration taken, May 21, 2021. Photo: Reuters
Middle East

UAE approves Sinopharm's protein-based vaccine

A nurse holds a vial of China's Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria
Covid-19 in Bangladesh

Local production of Sinopharm vaccine uncertain

Photo: Reuters
Coronavirus chronicle

Sinopharm Covid-19 booster weaker against Omicron - study

A nurse holds a vial of China's Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria
Coronavirus chronicle

Canada to allow entry of travelers fully vaccinated with Sinopharm

Photo: Courtesy
Covid-19 in Bangladesh

Special vaccination campaign at community clinics from Saturday

Photo: Reuters
Covid-19 in Bangladesh

50 lakh more doses of Sinopharm vaccine reach Dhaka

Over 54 lakh doses of Sinopharm vaccine reach Dhaka
Covid-19 in Bangladesh

Over 54 lakh doses of Sinopharm vaccine reach Dhaka

File photo
Covid-19 in Bangladesh

20 lakh Sinopharm jabs arrived from China

Pfizer-BioNTech mRNA vaccineVincent Kraut/ Photonews via Getty Images
Bangladesh

10 lakh Pfizer doses to arrive Wednesday

A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang
Coronavirus chronicle

Peru study finds Sinopharm Covid vaccine 50.4% effective against infections

File photo
Covid-19 in Bangladesh

10 lakh Sinopharm doses arrive from China

  • Show More
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]